Cryptococcosis Therapeutics Market Report 2025

The cryptococcosis therapeutics market size has grown strongly in recent years. It will grow from $3.91 billion in 2024 to $4.13 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth during the historic period can be attributed to the increasing prevalence of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), heightened awareness of fungal infections, improved availability of antifungal medications, expansion of global surveillance and fungal disease awareness programs, and the rise of non-governmental health initiatives.

The cryptococcosis therapeutics market size is expected to see strong growth in the next few years. It will grow to $5.07 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The projected growth in the forecast period can be attributed to increasing investments in antifungal research and novel drug development, the rising prevalence of immunosuppressive conditions and treatments, the growing global burden of fungal diseases, and the heightened demand for rapid diagnostic tools and combination therapies. Key trends expected during this period include a move toward combination antifungal treatments, the development of next-generation antifungals with innovative mechanisms, enhanced integration of fungal disease management, adoption of advanced drug delivery technologies, and the incorporation of artificial intelligence and machine learning.

The increasing prevalence of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) is anticipated to drive the growth of the cryptococcosis therapeutics market in the coming years. HIV/AIDS is a chronic and life-threatening condition caused by a virus that attacks the immune system, making individuals more susceptible to infections and diseases. The rising prevalence in certain areas is attributed to limited access to healthcare services, which affects early diagnosis, continuous treatment, and effective prevention. Cryptococcosis therapeutics are crucial for managing HIV/AIDS as they target opportunistic fungal infections that commonly affect immunocompromised patients. These therapeutics improve patient outcomes by reducing the risk of severe complications like cryptococcal meningitis, thereby enhancing quality of life and supporting long-term disease management. For example, in October 2024, the UK Health Security Agency reported 6,008 HIV diagnoses in England for 2023 (including cases diagnosed abroad), reflecting a 51% increase from 3,975 cases in 2022. Consequently, the growing prevalence of HIV/AIDS is propelling the cryptococcosis therapeutics market.

Rising healthcare expenditure is also expected to contribute significantly to the growth of the cryptococcosis therapeutics market. Healthcare expenditure includes all financial resources spent on medical services, treatments, research, facilities, and public health programs aimed at improving health outcomes. This increase is largely driven by an aging population that requires more medical care and long-term healthcare services. Higher healthcare spending supports cryptococcosis therapeutics by improving access to advanced treatments, facilitating early diagnosis, and funding research into more effective antifungal drugs. For instance, in December 2024, the Centers for Medicare & Medicaid Services (CMS) reported that national health expenditures in the U.S. rose by 7.5% to $4.9 trillion in 2023, representing 17.6% of the gross domestic product (GDP). Moreover, between 2023 and 2032, national health expenditures are projected to grow at an average annual rate of 5.6%, increasing healthcare’s share of GDP from 17.3% in 2022 to 19.7% in 2032. Therefore, rising healthcare expenditure is driving market growth for cryptococcosis therapeutics.

Key companies in the cryptococcosis therapeutics market are focused on developing innovative treatments and securing regulatory approvals for drugs like azole antifungals to improve efficacy, address drug resistance, and expand their market share. Azole antifungal drugs inhibit fungal growth by blocking the synthesis of ergosterol, a critical component of fungal cell membranes. For example, in December 2022, Asahi Kasei Pharma Corporation, a pharmaceutical company based in Japan, obtained approval from Japan’s Ministry of Health, Labour, and Welfare (MHLW) to manufacture and sell Cresemba capsules (100 mg) and intravenous infusion (200 mg) for treating serious fungal infections such as aspergillosis, mucormycosis, and cryptococcosis. Cresemba (isavuconazonium sulfate) works by disrupting ergosterol production, causing fungal cell death. The capsules are approved for patients aged six years and older (weighing at least 16 kg), while the intravenous form is suitable for patients aged one year and above.

Major players in the cryptococcosis therapeutics market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Eisai Co. Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Takeda Pharmaceutical Company Limited, Luminex Corporation, Evotec SE, Kaken Pharmaceutical Co. Ltd., Basilea Pharmaceutica AG, Vical Incorporated, F2G Limited, Century Pharmaceuticals Ltd., LGM Pharma LLC, Zeon Health Industries Pvt. Ltd., and Matinas BioPharma Holdings Inc.

North America was the largest region in the cryptococcosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cryptococcosis therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cryptococcosis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cryptococcosis therapeutics market consists of revenues earned by entities by providing services such as diagnosis, antifungal drug administration, patient monitoring, treatment planning, disease management, and post-treatment care. The market value includes the value of related goods sold by the service provider or included within the service offering. The cryptococcosis therapeutics market also includes sales of polyene antifungals, azole antifungals, pyrimidine analogues, protein/enzyme inhibitors, and repurposed drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The cryptococcosis therapeutics market research report is one of a series of new reports that provides cryptococcosis therapeutics market statistics, including cryptococcosis therapeutics industry global market size, regional shares, competitors with a cryptococcosis therapeutics market share, detailed cryptococcosis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the cryptococcosis therapeutics industry. This cryptococcosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cryptococcosis therapeutics encompass the range of medical treatments aimed at managing cryptococcosis, a serious fungal infection primarily caused by Cryptococcus neoformans or Cryptococcus gattii. This infection mainly affects individuals with compromised immune systems. The primary goal of these treatments is to control the spread of the fungus, alleviate symptoms, and prevent severe complications such as meningitis.

The main categories of cryptococcosis therapeutics include branded and generic drugs. Branded medications are prescription drugs marketed under trademarked names by pharmaceutical companies. These treatments involve drugs like amphotericin B, flucytosine, fluconazole, among others, and can be administered orally, intravenously, or via inhalation. Distribution channels for these therapeutics include hospital pharmacies, retail pharmacies, and online pharmacies, catering to end users such as hospitals, ambulatory surgical centers, and related healthcare facilities.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.